Covered recipient · General Payments record
BRUCE RANKIN
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$6,373.98
97 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $3,980.38 | 13 |
| Food and Beverage | $2,387.60 | 83 |
| Education | $6.00 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $3,114.50 | 17 |
| Merck Sharp & Dohme Corporation | $2,265.12 | 16 |
| AstraZeneca Pharmaceuticals LP | $244.37 | 18 |
| Novo Nordisk Inc | $180.31 | 9 |
| Astellas Pharma US Inc | $99.72 | 5 |
| Teva Pharmaceuticals USA, Inc. | $94.98 | 7 |
| GlaxoSmithKline, LLC. | $69.96 | 5 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $61.73 | 4 |
| Allergan Inc. | $51.13 | 3 |
| Amgen Inc. | $44.90 | 3 |
| Lilly USA, LLC | $42.33 | 3 |
| Novartis Pharmaceuticals Corporation | $36.03 | 2 |
| SANOFI-AVENTIS U.S. LLC | $20.28 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $16.56 | 2 |
| Ultragenyx Pharmaceutical Inc. | $16.15 | 1 |
| Amarin Pharma Inc. | $15.91 | 1 |
Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRUCE RANKIN
NPI 1922027853 · CMS profile ID 132925
Allopathic & Osteopathic Physicians / Family Medicine
DELAND, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1922027853?year=2019&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922027853?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922027853?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- BRUCE RANKIN, NPI 1922027853, CMS profile ID 132925, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1922027853?year=2019&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
97 matching records · $6,373.98 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–97 of 97.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corporation | $119.98 | 05/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695806169 | CMS |
| Merck Sharp & Dohme Corporation | $13.61 | 05/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695806173 | CMS |
| Merck Sharp & Dohme Corporation | $81.19 | 05/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695804337 | CMS |
| Merck Sharp & Dohme Corporation | $103.13 | 05/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695806167 | CMS |
| Merck Sharp & Dohme Corporation | $247.06 | 05/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695807713 | CMS |
| Novo Nordisk Inc | $22.77 | 05/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 669601871 | CMS |
| Merck Sharp & Dohme Corporation | $1,195.04 | 05/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695806171 | CMS |
| Merck Sharp & Dohme Corporation | $247.06 | 05/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695806175 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.57 | 05/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685899867 | CMS |
| Teva Pharmaceuticals USA, Inc. | $11.34 | 05/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697709771 | CMS |
| Novartis Pharmaceuticals Corporation | $13.57 | 05/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659791831 | CMS |
| Amarin Pharma Inc. | $15.91 | 05/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699146427 | CMS |
| Novartis Pharmaceuticals Corporation | $22.46 | 04/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659791835 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.64 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685638555 | CMS |
| Novo Nordisk Inc | $20.26 | 04/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 669556921 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14.03 | 04/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700170739 | CMS |
| Novo Nordisk Inc | $21.27 | 04/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 669556917 | CMS |
| PFIZER INC. | $302.62 | 04/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672596859 | CMS |
| Merck Sharp & Dohme Corporation | $8.87 | 04/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695427507 | CMS |
| Teva Pharmaceuticals USA, Inc. | $12.30 | 04/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697765849 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.86 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685699413 | CMS |
| Novo Nordisk Inc | $20.26 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 669556919 | CMS |
| PFIZER INC. | $10.21 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672143805 | CMS |
| Astellas Pharma US Inc | $19.48 | 03/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655736999 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.58 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685218793 | CMS |
| AstraZeneca Pharmaceuticals LP | $6.00 | 03/26/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685284277 | CMS |
| Merck Sharp & Dohme Corporation | $13.56 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695391227 | CMS |
| Teva Pharmaceuticals USA, Inc. | $15.35 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697696545 | CMS |
| PFIZER INC. | $329.92 | 03/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672166879 | CMS |
| PFIZER INC. | $224.87 | 03/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672181391 | CMS |
| Astellas Pharma US Inc | $19.03 | 03/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655736997 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.44 | 03/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700170741 | CMS |
| Amgen Inc. | $15.83 | 03/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662228137 | CMS |
| PFIZER INC. | $290.00 | 03/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672596855 | CMS |
| GlaxoSmithKline, LLC. | $18.90 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671466017 | CMS |
| GlaxoSmithKline, LLC. | $14.03 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670833131 | CMS |
| Novo Nordisk Inc | $19.75 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 669461611 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1.26 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682040595 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $15.30 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 682087673 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.25 | 02/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685665651 | CMS |
| Novo Nordisk Inc | $16.48 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 668785709 | CMS |
| PFIZER INC. | $427.93 | 01/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672174247 | CMS |
| PFIZER INC. | $270.07 | 01/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672216159 | CMS |
| PFIZER INC. | $101.27 | 01/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672251701 | CMS |
| Astellas Pharma US Inc | $24.61 | 01/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655736995 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.70 | 01/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685827069 | CMS |
| Teva Pharmaceuticals USA, Inc. | $13.23 | 01/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697679681 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,755.45 | 1 |
| PY2025 | Principal investigator | $4,230,288.19 | 209 |
| PY2024 | Recipient | $1,330.16 | 13 |
| PY2024 | Principal investigator | $3,187,354.20 | 327 |
| PY2023 | Recipient | $893.27 | 4 |
| PY2023 | Principal investigator | $6,323,793.75 | 2,767 |
| PY2022 | Recipient | $462.00 | 2 |
| PY2022 | Principal investigator | $6,941,300.42 | 589 |
| PY2021 | Recipient | $15.00 | 1 |
| PY2021 | Principal investigator | $10,036,876.19 | 348 |
| PY2020 | Recipient | $10,602.17 | 4 |
| PY2020 | Principal investigator | $3,545,507.10 | 644 |
| PY2019 | Principal investigator | $2,410,610.06 | 875 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
210 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $79.62 | 12/31/2025 | Non-covered Recipient Entity Accel Research Sites-DeLand Clinical Research Unit | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age | No dispute reported | 06/30/2026 | 1232932986 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,357.20 | 12/22/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108641 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,000.00 | 12/19/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192680 |
| Principal investigator 1 | ModernaTX, Inc. | $1,022.58 | 12/19/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001767 |
| Principal investigator 1 | ModernaTX, Inc. | $40,285.70 | 12/19/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001797 |
| Principal investigator 1 | ModernaTX, Inc. | $6,029.10 | 12/19/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001803 |
| Principal investigator 1 | Eli Lilly and Company | $471.45 | 12/17/2025 | Non-covered Recipient Entity MERIDIEN RESEARCH | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | No dispute reported | 06/30/2026 | 1187886718 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,622.00 | 12/12/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192712 |
| Principal investigator 1 | Eli Lilly and Company | $525.01 | 12/11/2025 | Non-covered Recipient Entity SOUTHERN CALIFORNIA DERMATOLOGY INC | RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | No dispute reported | 06/30/2026 | 1187887442 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,682.50 | 12/09/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108633 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,000.00 | 12/05/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108626 |
| Principal investigator 1 | ABBVIE INC. | $8,100.00 | 12/04/2025 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH-DELAND LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202526530 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 12/04/2025 | Non-covered Recipient Entity Accel Research Sites Deland | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220997050 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $391.52 | 12/03/2025 | Non-covered Recipient Entity Accel Research Sites Deland | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220807075 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $600.00 | 12/02/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108618 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Accel Research Sites Deland | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220718121 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $1,396.75 | 12/01/2025 | Non-covered Recipient Entity ACCEL RESEARCH DELAND | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy? | No dispute reported | 06/30/2026 | 1214123468 |
| Principal investigator 1 | ModernaTX, Inc. | $4,090.32 | 11/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001733 |
| Principal investigator 1 | ModernaTX, Inc. | $39,134.68 | 11/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001751 |
| Principal investigator 1 | ModernaTX, Inc. | $6,373.62 | 11/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001789 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $16,500.40 | 11/21/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108594 |
| Principal investigator 1 | Eli Lilly and Company | $1,020.92 | 11/19/2025 | Non-covered Recipient Entity MERIDIEN RESEARCH | RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187886716 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,194.00 | 11/19/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192695 |
| Principal investigator 1 | ABBVIE INC. | $287.73 | 11/18/2025 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH-DELAND LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202524561 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $8,248.50 | 11/18/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108587 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $279,868.17 | 11/14/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108556 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,497.90 | 11/14/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108566 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,287.02 | 11/14/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108571 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $148.05 | 11/14/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108583 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,899.00 | 11/07/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192703 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Accel Research Sites Deland | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220718119 |
| Principal investigator 1 | ModernaTX, Inc. | $1,315.60 | 10/30/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 10/27/2025 | Non-covered Recipient Entity Accel Research Sites Deland | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220718123 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 10/27/2025 | Non-covered Recipient Entity Accel Research Sites Deland | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220718125 |
| Principal investigator 1 | ModernaTX, Inc. | $1,363.44 | 10/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001761 |
| Principal investigator 1 | ModernaTX, Inc. | $6,488.46 | 10/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001831 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $29,216.74 | 10/23/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108600 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $122,574.40 | 10/23/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108608 |
| Principal investigator 1 | ModernaTX, Inc. | $4,000.00 | 10/15/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253001721 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 10/15/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253001807 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $10,987.56 | 10/10/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108543 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 10/01/2025 | Non-covered Recipient Entity Accel Research Sites Deland | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220718111 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 10/01/2025 | Non-covered Recipient Entity Accel Research Sites Deland | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220718113 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 10/01/2025 | Non-covered Recipient Entity Accel Research Sites Deland | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220718115 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Accel Research Sites Deland | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220718117 |
| Principal investigator 1 | ModernaTX, Inc. | $6,220.50 | 09/29/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001729 |
| Principal investigator 1 | ModernaTX, Inc. | $1,206.60 | 09/29/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001753 |
| Principal investigator 1 | ModernaTX, Inc. | $12,611.82 | 09/29/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001827 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,345.00 | 09/19/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192772 |
| Recipient | Eli Lilly and Company | $1,755.45 | 09/12/2025 | Covered Recipient Physician | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187876319 |
| Principal investigator 1 | Janssen Research & Development, LLC | $486.00 | 09/12/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192877 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 09/11/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253001719 |
| Principal investigator 1 | Eli Lilly and Company | $275,199.00 | 09/02/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 | No dispute reported | 06/30/2026 | 1187892474 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,250.00 | 08/29/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192113218 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,200.00 | 08/29/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192174280 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 08/29/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192174304 |
| Principal investigator 1 | ModernaTX, Inc. | $12,952.68 | 08/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001725 |
| Principal investigator 1 | ModernaTX, Inc. | $16,892.40 | 08/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001731 |
| Principal investigator 1 | ModernaTX, Inc. | $833.62 | 08/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001737 |
| Principal investigator 1 | ModernaTX, Inc. | $7,062.66 | 08/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001739 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,639.00 | 08/25/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192765 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,858.00 | 08/22/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192909 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,371.86 | 08/20/2025 | Non-covered Recipient Entity ACCEL RESEARCH SITES | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185553555 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,172.00 | 08/08/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192794 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $10.66 | 07/29/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 | No dispute reported | 06/30/2026 | 1187893728 |
| Principal investigator 1 | ModernaTX, Inc. | $1,206.60 | 07/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001749 |
| Principal investigator 1 | ModernaTX, Inc. | $681.72 | 07/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001765 |
| Principal investigator 1 | ModernaTX, Inc. | $1,703.46 | 07/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001795 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 07/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253001805 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,029.00 | 07/23/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192725 |
| Principal investigator 1 | ModernaTX, Inc. | $182.00 | 07/23/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001747 |
| Principal investigator 1 | ModernaTX, Inc. | $1,248.00 | 07/23/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001821 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 07/21/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH - DELAND LLC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1192113212 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,250.00 | 07/21/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH - DELAND LLC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1192174293 |
| Principal investigator 1 | ABBVIE INC. | $400.00 | 07/08/2025 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH-DELAND LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202497044 |
| Principal investigator 1 | ModernaTX, Inc. | $1,491.75 | 07/07/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252990120 |
| Principal investigator 1 | ABBVIE INC. | $2,239.17 | 07/02/2025 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH-DELAND LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202494217 |
| Principal investigator 1 | ModernaTX, Inc. | $5,112.90 | 06/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001735 |
| Principal investigator 1 | ModernaTX, Inc. | $4,826.40 | 06/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001757 |
| Principal investigator 1 | ModernaTX, Inc. | $5,856.84 | 06/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001835 |
| Principal investigator 1 | Janssen Research & Development, LLC | $586.00 | 06/25/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192848 |
| Principal investigator 1 | Janssen Research & Development, LLC | $510.00 | 06/23/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192757 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,897.81 | 06/20/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192174456 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,732.00 | 06/20/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175192687 |
| Principal investigator 1 | Janssen Research & Development, LLC | $51,783.00 | 06/20/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192739 |
| Principal investigator 1 | ModernaTX, Inc. | $1,667.24 | 06/18/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001727 |
| Principal investigator 1 | ModernaTX, Inc. | $51,883.80 | 06/18/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001771 |
| Principal investigator 1 | ModernaTX, Inc. | $6,239.64 | 06/18/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001779 |
| Principal investigator 1 | ModernaTX, Inc. | $6,135.48 | 06/18/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001825 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $600.00 | 06/16/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108550 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,100.00 | 06/16/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108562 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,500.00 | 06/16/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108577 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,250.00 | 06/13/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108498 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $24,500.00 | 06/13/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108505 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $859.10 | 06/13/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108515 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $9,984.02 | 06/13/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108521 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,748.80 | 06/13/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108526 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $22,535.40 | 06/13/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108535 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $212,517.14 | 06/12/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108488 |
| Principal investigator 1 | ModernaTX, Inc. | $2,288.00 | 06/11/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001785 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,000.00 | 06/09/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192113236 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $300.00 | 06/09/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192174296 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,749.44 | 06/09/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108483 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $13,700.00 | 06/06/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108477 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,050.00 | 06/05/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192113228 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,294.00 | 06/02/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192817 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $600.00 | 06/02/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108461 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,409.82 | 06/02/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108467 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $19,209.60 | 06/02/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108473 |
| Principal investigator 1 | ModernaTX, Inc. | $39,817.80 | 05/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001763 |
| Principal investigator 1 | ModernaTX, Inc. | $23,178.48 | 05/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001791 |
| Principal investigator 1 | ModernaTX, Inc. | $6,947.82 | 05/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001813 |
| Principal investigator 1 | ModernaTX, Inc. | $833.62 | 05/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001829 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,000.00 | 05/28/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108430 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $12,780.00 | 05/28/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108435 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,000.00 | 05/28/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108441 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $375.69 | 05/26/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192113222 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,327.42 | 05/26/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192174278 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,296.89 | 05/26/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192174284 |
| Principal investigator 1 | Novo Nordisk AS | $2,750.00 | 05/23/2025 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1213757257 |
| Principal investigator 1 | Novo Nordisk AS | $3,366.89 | 05/23/2025 | Non-covered Recipient Entity ACCEL RESEARCH SITES | NN9536-7545 | No dispute reported | 06/30/2026 | 1213780569 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,616.00 | 05/20/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175192788 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,382.76 | 05/16/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108395 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $87,869.60 | 05/16/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108402 |
| Principal investigator 1 | ModernaTX, Inc. | $105.00 | 05/07/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | No dispute reported | 06/30/2026 | 1252990122 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 05/07/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253001769 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,590.18 | 05/02/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108384 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,500.00 | 04/30/2025 | Non-covered Recipient Entity ACCEL RESEARCH SITES | A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma | No dispute reported | 06/30/2026 | 1185553553 |
| Principal investigator 1 | ModernaTX, Inc. | $25,905.36 | 04/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001723 |
| Principal investigator 1 | ModernaTX, Inc. | $6,947.82 | 04/28/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001755 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $13,446.72 | 04/28/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108419 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $548,680.90 | 04/28/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108425 |
| Principal investigator 1 | Eli Lilly Export S.A. Puerto Rico Branch | $12,597.89 | 04/24/2025 | Non-covered Recipient Entity SOUTHERN CALIFORNIA DERMATOLOGY INC | A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON TABLET ONCE DAILY COMPARED WITH PLACEBO IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH AND WITHOUT TYPE 2 DIABETES: J2A-MC-GZP1, J2A-MC-GZP2 | No dispute reported | 06/30/2026 | 1187890904 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $600.00 | 04/24/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1226108408 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $600.00 | 04/24/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108414 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,009.00 | 04/23/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192866 |
| Principal investigator 1 | ModernaTX, Inc. | $26,453.41 | 04/18/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252990118 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,950.00 | 04/17/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175192748 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,816.00 | 04/17/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175192841 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $450.00 | 04/04/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192113194 |
| Principal investigator 1 | ABBVIE INC. | $574.77 | 04/03/2025 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH-DELAND LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202472727 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,787.27 | 04/02/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH - DELAND LLC | A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY T | No dispute reported | 06/30/2026 | 1192174289 |
| Principal investigator 1 | ModernaTX, Inc. | $25,079.60 | 04/01/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001743 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $88.32 | 04/01/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108367 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,152.30 | 04/01/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108378 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,897.81 | 03/26/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192113198 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,010.00 | 03/24/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175192902 |
| Principal investigator 1 | ModernaTX, Inc. | $6,048.24 | 03/24/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001773 |
| Principal investigator 1 | ModernaTX, Inc. | $31,699.98 | 03/24/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001801 |
| Principal investigator 1 | ModernaTX, Inc. | $19,068.48 | 03/24/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001823 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,076.00 | 03/21/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192831 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $19,800.00 | 03/21/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226108362 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $64,000.26 | 03/21/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108371 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,200.00 | 03/20/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108357 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $185.54 | 03/18/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND-DELA | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | No dispute reported | 06/30/2026 | 1192113934 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $140,819.34 | 03/11/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108353 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $700.00 | 03/05/2025 | Non-covered Recipient Entity Accel Research Sites Deland | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220718103 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 03/05/2025 | Non-covered Recipient Entity Accel Research Sites Deland | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220718105 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,350.00 | 03/05/2025 | Non-covered Recipient Entity Accel Research Sites Deland | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220718107 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $615.00 | 03/05/2025 | Non-covered Recipient Entity Accel Research Sites Deland | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220718109 |
| Principal investigator 1 | ModernaTX, Inc. | $7,024.38 | 02/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001775 |
| Principal investigator 1 | ModernaTX, Inc. | $55,693.60 | 02/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001793 |
| Principal investigator 1 | ModernaTX, Inc. | $3,866.28 | 02/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001811 |
| Principal investigator 1 | ModernaTX, Inc. | $26,246.22 | 02/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001817 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,330.24 | 02/24/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192113206 |
| Principal investigator 1 | ABBVIE INC. | $122.32 | 02/20/2025 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH-DELAND LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202452762 |
| Principal investigator 1 | ABBVIE INC. | $343.33 | 02/20/2025 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH-DELAND LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202452767 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,623.00 | 02/19/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175192778 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,931.00 | 02/19/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192885 |
| Principal investigator 1 | ModernaTX, Inc. | $1,700.64 | 02/19/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001833 |
| Principal investigator 1 | Eli Lilly and Company | $28,763.40 | 02/18/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS | No dispute reported | 06/30/2026 | 1187892472 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,314.76 | 02/17/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108705 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,488.14 | 02/14/2025 | Non-covered Recipient Entity Accel Research Sites Deland | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220718093 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,956.46 | 02/14/2025 | Non-covered Recipient Entity Accel Research Sites Deland | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220718095 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,485.00 | 02/14/2025 | Non-covered Recipient Entity Accel Research Sites Deland | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220718097 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,099.48 | 02/14/2025 | Non-covered Recipient Entity Accel Research Sites Deland | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220718099 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,887.96 | 02/14/2025 | Non-covered Recipient Entity Accel Research Sites Deland | MRD/PoCP study in NFLD (12 wks) | No dispute reported | 06/30/2026 | 1220718101 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20.00 | 02/14/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175192719 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $600.00 | 02/12/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1226108699 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,162.46 | 02/10/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108692 |
| Principal investigator 1 | ABBVIE INC. | $1,199.45 | 02/06/2025 | Non-covered Recipient Entity UNIV CLINICAL RESEARCH-DELAND LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202446907 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $169.20 | 02/03/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108674 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $42,288.72 | 02/03/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | No dispute reported | 06/30/2026 | 1226108680 |
| Principal investigator 1 | Janssen Research & Development, LLC | $895.00 | 01/31/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175333453 |
| Principal investigator 1 | ModernaTX, Inc. | $1,950.00 | 01/30/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001781 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 01/29/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252990116 |
| Principal investigator 1 | ModernaTX, Inc. | $54,530.15 | 01/29/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252990124 |
| Principal investigator 1 | ModernaTX, Inc. | $12,952.71 | 01/29/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252990126 |
| Principal investigator 1 | ModernaTX, Inc. | $16,076.61 | 01/29/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253001717 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 01/29/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1253001745 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $83,233.32 | 01/29/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108723 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $15,280.00 | 01/28/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108718 |
| Principal investigator 1 | Eli Lilly and Company | $505.22 | 01/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS | No dispute reported | 06/30/2026 | 1187890744 |
| Principal investigator 1 | ModernaTX, Inc. | $9,971.94 | 01/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001741 |
| Principal investigator 1 | ModernaTX, Inc. | $42,948.36 | 01/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001759 |
| Principal investigator 1 | ModernaTX, Inc. | $59,564.05 | 01/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001777 |
| Principal investigator 1 | ModernaTX, Inc. | $102,635.72 | 01/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001783 |
| Principal investigator 1 | ModernaTX, Inc. | $16,039.32 | 01/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001799 |
| Principal investigator 1 | ModernaTX, Inc. | $95,342.40 | 01/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001815 |
| Principal investigator 1 | ModernaTX, Inc. | $10,442.55 | 01/27/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH DELAND LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001819 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $169,889.85 | 01/24/2025 | Non-covered Recipient Entity ACCEL RESEARCH DELAND | A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214124034 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,586.00 | 01/22/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175192825 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $204.45 | 01/22/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). | No dispute reported | 06/30/2026 | 1226108712 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,890.00 | 01/21/2025 | Non-covered Recipient Entity Univ Clinic Rsrch - Deland, Llc | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175192856 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $17,084.00 | 01/17/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH LLC | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185553557 |
| Principal investigator 1 | ModernaTX, Inc. | $149.67 | 01/16/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1253001809 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,693.42 | 01/09/2025 | Non-covered Recipient Entity UNIVERSITY CLINICAL RESEARCH-DELAND LLC | A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL | No dispute reported | 06/30/2026 | 1192174300 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $43,943.34 | 01/07/2025 | Non-covered Recipient Entity University Clinical Research Dela Llc | A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226108687 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $451,283.54 | 01/01/2025 | Non-covered Recipient Entity ACCEL RESEARCH DELAND | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214123466 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $143,156.11 | 01/01/2025 | Non-covered Recipient Entity ACCEL RESEARCH DELAND | A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214123736 |